{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enasidenib&page=2", "query": { "intervention": "Enasidenib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enasidenib&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enasidenib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T03:57:27.748Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06240754", "title": "Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance", "CCUS Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-10-10", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06240754" }, { "nct_id": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Acute Myeloid Leukemia, Myelodysplasia-Related", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olutasidenib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2024-06-18", "completion_date": "2029-05-15", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 337, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564390" }, { "nct_id": "NCT03825796", "title": "CPX-351 Plus Enasidenib for Relapsed AML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Myeloid Leukemia" ], "interventions": [ { "name": "Enasidenib Mesylate", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-04-12", "completion_date": "2024-09-01", "has_results": false, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 3, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03825796" }, { "nct_id": "NCT06672146", "title": "Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2025-05-16", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 134, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 114 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672146" }, { "nct_id": "NCT04655391", "title": "Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Myeloid Leukemia" ], "interventions": [ { "name": "Bosutinib Monohydrate", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Enasidenib Mesylate", "type": "DRUG" }, { "name": "Gilteritinib Fumarate", "type": "DRUG" }, { "name": "Glasdegib Maleate", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-06-25", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04655391" }, { "nct_id": "NCT03683433", "title": "Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Chronic Myelomonocytic Leukemia", "IDH2 Gene Mutation", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Enasidenib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-09-18", "completion_date": "2027-09-20", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03683433" }, { "nct_id": "NCT03728335", "title": "Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Enasidenib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-12-23", "completion_date": "2027-01-11", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 2, "location_summary": "Duarte, California • Tampa, Florida", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03728335" }, { "nct_id": "NCT03881735", "title": "Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blasts Under 5 Percent of Peripheral Blood White Cells", "Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level", "IDH2 Gene Mutation", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-12-02", "completion_date": "2022-11-19", "has_results": false, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 2, "location_summary": "Buffalo, New York • East Hills, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "East Hills", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03881735" }, { "nct_id": "NCT05102370", "title": "A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance", "CCUS Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-10-06", "completion_date": "2026-01-26", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 12, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Basking Ridge, New Jersey + 9 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05102370" }, { "nct_id": "NCT04075747", "title": "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Midostaurin", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 57, "start_date": "2019-12-02", "completion_date": "2023-09-12", "has_results": false, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-10-01T03:57:27.748Z", "location_count": 10, "location_summary": "Duarte, California • Palo Alto, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04075747" } ] }